Nov 2, 10:50 AM ET
Supernus Pharmaceuticals completed a merger on November 2, 2026, and asked Nasdaq to suspend trading in its common stock before the market opened that day. The company will be removed from Nasdaq and will stop being a publicly listed stock, so shares will no longer trade on any national securities exchange.
- Merger consummated November 2, 2026; trading in Supernus common stock suspended before market open that day
- Company requested Nasdaq file a Form 25 to delist the stock and deregister it under Section 12(b)
- After Form 25 takes effect, company intends to file Form 15 to deregister under Section 12(g) and suspend SEC reporting obligations
Read the filing on SEC.gov ↗
Nov 2, 9:28 AM ET
Supernus Pharmaceuticals has completed its merger with Indivior Pharmaceuticals, forming a combined entity operating as Supernus, Inc. Under the terms of the agreement, Supernus stockholders received 1.5401 shares of Indivior common stock for each share owned, resulting in former Indivior stockholders owning approximately 56.5% and former Supernus stockholders owning approximately 43.5% of the combined company. The company also entered into a $650 million senior secured term loan facility to help fund a $1.0 billion special cash dividend to legacy Indivior stockholders.
- The merger was completed on November 2, 2026, combining Supernus Pharmaceuticals and Indivior Pharmaceuticals into Supernus, Inc.
- Supernus stockholders received 1.5401 shares of Indivior common stock for each share of Supernus common stock owned.
- The combined company secured a $650 million term loan facility with Citibank, N.A. to help finance a $1.0 billion aggregate special cash dividend to legacy Indivior stockholders.
- Former Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.
Read the filing on SEC.gov ↗
Oct 29, 4:08 PM ET
Supernus reported third-quarter 2026 total revenues of $226.8 million, up 18% from a year earlier, and net earnings of $20.9 million, or $0.35 per diluted share, compared with a net loss of $45.1 million a year earlier. The company raised its full-year 2026 total revenue and GAAP operating earnings guidance, but the guidance will no longer apply if the Indivior merger closes as expected on November 2, 2026.
- Q3 2026 net earnings were $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or $0.80 per share, in Q3 2025.
- Total revenues were $226.8 million, up from $192.1 million; ONAPGO net sales rose to $17.1 million from $6.8 million.
- 2026 total revenue guidance was raised to $875 million to $900 million from $860 million to $890 million.
- The Indivior merger is expected to close November 2, 2026; Supernus common stock is expected to trade under SUPN on November 3, 2026.
Read the filing on SEC.gov ↗
Oct 26, 4:41 PM ET
Supernus Pharmaceuticals terminated its uncommitted UBS revolving credit line on October 20, 2026, in connection with its planned business combination with Indivior Pharmaceuticals and a new senior secured credit facility for the combined company. The company reported no outstanding borrowings and no early termination penalties, so the termination itself has no direct financial cost disclosed in the filing.
- Terminated UBS Credit Line Agreement dated February 8, 2023, with UBS Bank USA on October 20, 2026
- No advances, letters of credit or other borrowings were outstanding at termination
- No early termination penalties were incurred; the Bank's security interests in the collateral were released
- Termination tied to the pending combination with Indivior Pharmaceuticals under a merger agreement dated August 1, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.